Circulating miR-195 as a Therapeutic Biomarker in Turkish Breast Cancer Patients |
Cecener, Gulsah
(Department of Medical Biology, Medical Faculty, Uludag University)
Ak, Secil (Department of Medical Biology, Medical Faculty, Uludag University) Eskiler, Gamze Guney (Department of Medical Biology, Medical Faculty, Uludag University) Demirdogen, Elif (Department of Medical Biology, Medical Faculty, Uludag University) Erturk, Elif (Department of Medical Biology, Medical Faculty, Uludag University) Gokgoz, Sehsuvar (Department of General Surgery, Medical Faculty, Uludag University) Polatkan, Volkan (Department of General Surgery, Medical Faculty, Uludag University) Egeli, Unal (Department of Medical Biology, Medical Faculty, Uludag University) Tunca, Berrin (Department of Medical Biology, Medical Faculty, Uludag University) Tezcan, Gulcin (Department of Medical Biology, Medical Faculty, Uludag University) Topal, Ugur (Department of Radiology, Medical Faculty, Uludag University) Tolunay, Sahsine (Department of Pathology, Medical Faculty, Uludag University) Tasdelen, Ismet (Department of General Surgery, Medical Faculty, Uludag University) |
1 | Kayani MR, Kayani MA, Malik FA et al (2011). Role of miRNAs in breast cancer. Asian Pacific J Cancer Prev, 12, 3175-80. |
2 | Kosaka N, Iguchi H, Ochiya T, (2010). Circulating microRNA in body fluid: a new potential biomarker for cancer diagnosis and prognosis. Cancer Sci, 101, 2087-92. DOI |
3 |
Livak KJ, Schmittgen T.D, (2001). Analysis of relative gene expression data using real-time quantitative PCR and the 2- |
4 | Lowery AJ, Miller N, McNeill RE, et al (2008). MicroRNAs as prognostic indicators and therapeutic targets: potential effect on breast cancer management. Clin Cancer Res, 14, 360-5. DOI |
5 | Lu J, Getz G, Miska EA, et al (2005). MicroRNA expression profiles classify human cancers. Nature, 435, 834-8. DOI |
6 | Kavitha N, Vijayarathna S, Jothy SL, et al (2014). MicroRNAs: biogenesis, roles for carcinogenesis and as potential biomarkers for cancer diagnosis and prognosis. Asian Pac J Cancer Prev, 15, 7489-97. DOI |
7 | Madhavan D, Cuk K, Burwinkel B, et al (2013). Cancer diagnosis and prognosis decoded by blood-based circulating microRNA signatures. FGENE, 4. |
8 | Luo Q, Wei C, Li X, et al (2014). MicroRNA-195-5p is a potential diagnostic and therapeutic target for breast cancer. Oncol Reps, 31, 1096-102. DOI |
9 | Ma R, Jiang T, Kang X (2012). Circulating microRNAs in cancer: origin, function and application. JECCR, 31, 38. |
10 | Ma R, Jiang T, Kang X (2012). Circulating microRNAs in cancer: origin, function and application. J Exp Clin Can, 31, 38. DOI |
11 | Madhavan D, Zucknick M, Wallwiener M, et al (2012). Circulating miRNAs as surrogate markers for circulating tumor cells and prognostic markers in metastatic breast cancer. Clin Cancer Res, 18, 5972-82. DOI |
12 | Mirnezami AH, Pickard K, Zhang L, et al (2009). MicroRNAs: key players in carcinogenesis and novel therapeutic targets. Eur J Surg Oncol, 3, 339-47. |
13 | Shavers VL, Brown ML, (2002). Racial and ethnic disparities in the receipt of cancer treatment. J National Cancer Inst, 94, 334-57. DOI |
14 | Allegra A, Alonci A, Campo S, et al (2012). Circulating microRNA: New biomarkers in diagnosis, prognosis and treatment of cancer. Int J Oncol, 41, 1897-912. DOI |
15 | Aquilar F, Ramirez JA, Malagon-Santiago I, et al (2013). Serum circulating microRNA profiling for identification of potential breast cancer biomarkers. Disease Markers, 34, 163-169. DOI |
16 | Qu H, Xu W , Huang Y et al (2011). Circulating miRNAs: promising biomarkers of human cancer. Asian Pac J Cancer Prev, 12, 1117-25. |
17 | Roth C, Rack B, Muller V, et al (2010). Circulating microRNAs as blood-based markers for patients with primary and metastatic breast cancer. Breast Cancer Res, 12. |
18 | Roth C, Rack B, Muller V, et al (2010). Circulating microRNAs as blood-based markers for patients with primary and metastatic breast cancer. Breast Cancer Res, 12, 90. DOI |
19 | Sarfati D, Blakely T, Shaw C, et al (2006). Patterns of disparity: ethnic and socio-economic trends in breast cancer mortality in New Zealand. Cancer Causes Control, 17, 671-8. DOI |
20 | Schrauder MG, Strick R, Schulz-Wendtland R, et al (2012). Circulating micro-RNAs as potential blood-based markers for early stage breast cancer detection. PLoS One, 7, 1-9. |
21 | Shavers VL, Brown M.L, (2002). Racial and ethnic disparities in the receipt of cancer treatment. J National Cancer Inst, 94, 334-57. DOI |
22 | Shen J, Ambrosone CB, DiCioccio RA, et al (2008). A functional polymorphism in the miR-146a gene and age of familialbreast/ovarian cancer diagnosis. Carcinogenesis, 29, 1963-66. DOI |
23 | Si H, Sun X, Chen Y, et al (2013). Circulating microRNA-92a and microRNA-21 as novel minimally invasive biomarkers for primary breast cancer. J Cancer Res Clin Oncol, 139, 223-9. DOI |
24 | Sun Y, Wang M, Lin G, et al (2012). Serum microRNA-155 as a potential biomarker to track disease in breast cancer. PLoS One, 7. |
25 | Uchida N, Suda T, et al (2013). Effect of chemotherapy for Luminal A breast cancer. Acta Med, 56, 51-6. |
26 | Chen G, Wang J, Cui Q, (2013). Could circulating miRNAs contribute to cancer therapy? Trends Mol Med, 19, 71-3. DOI |
27 | Asaga S, Kuo C, Nguyen T, et al (2011). Direct serum assay for microRNA-21 concentrations in early and advanced breast cancer. Clin Chem, 57, 84-91. DOI |
28 | Calin GA, Croce CM, (2006). MicroRNA signatures in human cancers. Nature Reviews Cancer, 6, 857-66. DOI |
29 | Chan M, Liaw CS, Ji SM, (2013). Identification of circulating microRNA signatures for breast cancer detection. Clin Cancer Res, 19, 4477-87. DOI |
30 | Corcoran C, Friel AM, Duffy MJ, et al (2011). Intracellular and extracellular MicroRNAs in breast cancer. Clin Chem, 57, 18-32. DOI |
31 | Cortez MA, Welsh JW, Calin GA, (2012). Circulating microRNAs as noninvasive biomarkers in breast cancer. Recent Results Cancer Res, 195, 151-61. |
32 | Creighton CJ, (2012). The molecular profile of luminal B breast cancer. Biologics: Targets Therapy, 6, 289-97. |
33 | Cuk K, Zucknick M, Heil J, et al (2013). Circulating micrornas in plasma as early detection markers for breast cancer. Int J Cancer, 132, 1602-12. DOI |
34 | Demirdogen Sevinc E, Egeli U, Cecener G, et al (2015). Association of miR-1266 with Recurrence/Metastasis Potential in Estrogen Receptor Positive Breast Cancer. Asian Pac J Cancer Prev, 16, 291-7 DOI |
35 | Desantis C, Ma J, Bryan L, et al (2014). Breast cancer statistics. CA Cancer J Clin, 64, 52-62. DOI |
36 | EK Ng, Li R, Shin VY, et al (2013). Circulating microRNAs as specific biomarkers for breast cancer detection. PLoS One, 8, 531-41. |
37 | Wiencke JK (2004). Impact of race/ethnicity on molecular pathways in human cancer. Nat Rev Cancer, 4, 79-84. DOI |
38 | Vasudevan S, Tong YC, Steitz JA, (2007). Switching from repression to activation: MicroRNAs can up-regulate translation. Sci, 318, 1931-34. DOI |
39 | Wang H, Tan G, Dong L, et al (2012). Circulating MiR-125b as a marker predicting chemoresistance in breast cancer. PLoS One, 7. |
40 | Wang J, Zhang K, Liu S, et al (2014). Tumor-associated circulating microRNAs as biomarkers of cancer. Molecules, 19, 1912-38. DOI |
41 | Wu Q, Lu Z, Li H, et al (2011). Next-generation sequencing of microRNAs for breast cancer detection. J Biomed Biotechnol. |
42 | Wu X, Somlo G, Yu Y, et al (2012). De novo sequencing of circulating miRNAs identifies novel markers predicting clinical outcome of locally advanced breast cancer. J Transl Med, 10, 42. DOI |
43 | Yanagawa M, Ikemot K, Kawauchi S, et al (2012). Luminal A and Luminal B (HER2 negative) subtypes of breast cancer consist of a mixture of tumors with different genotypes. BMC Research Notes, 5, 376. DOI |
44 | Zhang H, Su B, Zhou QM, et al (2009). Differential expression |
45 | Heneghan HM, Miller N, Kelly R, et al (2010). Systemic miRNA-195 differentiates breast cancer from other malignancies and is a potential biomarker for detecting noninvasive and early stage disease. Oncologist, 15, 673-82. DOI |
46 | Erturk E, Cecener G, Egeli U, et al (2014). Expression status of let-7a and miR-335 among breast tumors in patients with and without germ-line BRCA mutations. Mol Cell Biochem, 395, 77-88. DOI |
47 | Filipowicz W, Bhattacharyya SN, Sonenberg N, (2008). Mechanisms of post-transcriptional regulation by microRNAs: are the answers in sight? Nature Reviews Genetics, 9, 102-14. DOI |
48 | He L, Hannon GJ (2004). MicroRNAs: Small RNAs with a big role in gene regulation. Nature Rev Genet, 5, 522-31. DOI |
49 | Heneghan HM, Miller N, Kerin MJ, (2011). Circulating microRNAs: promising breast cancer biomarkers. Breast Cancer Res, 13, 402. DOI |
50 | Heneghan HM, Miller N, Lowery AJ, et al (2010). Circulating microRNAs as novel minimally invasive biomarkers for breast cancer. Ann Surg, 251, 499-505. DOI |
51 | Iorio MV, Casalini P, Tagliabue E, et al (2008). MicroRNA profiling as a tool to understand prognosis, therapy response and resistance in breast cancer. European J Cancer, 44, 2753-9. DOI |
52 | Iorio MV, Ferracin M, Liu CG, (2005). MicroRNA gene expression deregulation in human breast cancer. Cancer Res, 65, 7065-70. DOI |
53 | Jack RH, Davies EA, Renshaw C, et al (2013). Differences in breast cancer hormone receptor status in ethnic groups: A London population. Eur J Cancer, 49, 696-702. DOI |
![]() |